MedPath

Artemisinin

Generic Name
Artemisinin
Drug Type
Small Molecule
Chemical Formula
C15H22O5
CAS Number
63968-64-9
Unique Ingredient Identifier
9RMU91N5K2
Background

Artemisinin has been used in trials studying the treatment of Schizophrenia, Malaria, Falciparum, and Plasmodium Falciparum.

Associated Conditions
Malaria caused by Plasmodium falciparum
Clinical Trials
Related News

A Study to Evaluate the Safety and Efficacy of OT-101+Artemisinin in Hospitalized COVID-19 Subjects

Phase 2
Conditions
COVID-19
Interventions
Drug: Placebo
First Posted Date
2021-03-16
Last Posted Date
2021-03-16
Lead Sponsor
Oncotelic Inc.
Target Recruit Count
18
Registration Number
NCT04801017
Locations
๐Ÿ‡ง๐Ÿ‡ท

Praxis Pesquisa Medica S / S Ltda, Jardim, Brazil

Evaluating the Efficacy of Artesunate in Adults With Mild Symptoms of COVID-19

Phase 2
Withdrawn
Conditions
Corona Virus Infection
Covid 19 Positive
Interventions
Other: placebo
First Posted Date
2020-05-13
Last Posted Date
2022-05-02
Lead Sponsor
Princess Nourah Bint Abdulrahman University
Registration Number
NCT04387240
Locations
๐Ÿ‡ธ๐Ÿ‡ฆ

Princess Nourah Bint Abdulrahman Univeristy, Riyadh, Central, Saudi Arabia

Parasitic Clearance and Recurrence Rates Among Patients With Vivax Malaria

First Posted Date
2013-02-05
Last Posted Date
2013-11-25
Lead Sponsor
Ministry of Health, Bhutan
Target Recruit Count
50
Registration Number
NCT01784315
Locations
๐Ÿ‡ง๐Ÿ‡น

Vector Diseases Control Program, Gelephu, Gelephu, Bhutan

๐Ÿ‡ง๐Ÿ‡น

Mr. Thinly, Sarpang, Bhutan

Artemisinin With Risperidone for First-Episode and Drug-Naive Schizophrenia

Phase 3
Completed
Conditions
Schizophrenia
Interventions
Other: Placebo
First Posted Date
2011-07-12
Last Posted Date
2016-07-12
Lead Sponsor
Beijing HuiLongGuan Hospital
Target Recruit Count
88
Registration Number
NCT01391403
Locations
๐Ÿ‡จ๐Ÿ‡ณ

Beijing HuiLongGuan hospital, Beijing, China

ยฉ Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy